Detection of Canine Transitional Cell Carcinoma Using a Bladder Tumor Antigen Urine Dipstick Test

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Canine transitional cell carcinoma (TCC) carries a poor prognosis in part due to late disease detection. The measurement of specific tumor markers shed in the urine may aid in sensitive, early disease detection and therefore improved prognosis. A 1-year prospective clinical trial was designed to assess the efficacy, sensitivity and specificity of the first generation Bard BTA test to diagnose TCC in dogs. This test is a qualitative, rapid, latex agglutination, dipstick test run on voided urine, which measures a glycoprotein antigen complex associated with bladder cancer in human patients. Sixty-five dogs were entered in the study: 20 TCC confirmed patients, 19 healthy controls and 26 urologic controls with a variety of conditions including urinary tract infection, crystalluria and proteinuria. Overall test sensitivity was 90% and specificity was 78%. False positive test results were noted in the presence of significant glucosuria (4+), proteinuria (4+), and pyuria or hematuria (> 30-40 WBC or RBC per hpf). Urine parameters that had no effect on efficacy included collection method (cystocentesis or free catch), pH, specific gravity, crystalluria, bilirubinuria, bacteriuria and casts. These data indicated that the Bard BTA test was sensitive for the detection of the bladder tumor-associated antigen complex in canine TCC. As evaluated, this test may serve as a useful adjunct to diagnosis, especially when cytology or biopsy is questionable or impractical. Furthermore, because of the high sensitivity of the test, it may be a practical screening test to rule out TCC in geriatric patients or patients with clinical signs related to the lower urinary tract, particularly before pyuria and hematuria develop which may interfere with test results.

Original languageEnglish (US)
Pages (from-to)33-38
Number of pages6
JournalVeterinary Clinical Pathology
Volume28
Issue number1
StatePublished - 1999

Fingerprint

Transitional Cell Carcinoma
Neoplasm Antigens
Urinary Bladder Neoplasms
carcinoma
Canidae
urine
Geriatrics
Cells
Urine
Cytology
antigens
Biopsy
dogs
Pyuria
Latex
Tumor Biomarkers
Density (specific gravity)
Hematuria
Glycoproteins
Screening

Keywords

  • Dipstick
  • Dog
  • Transitional cell carcinoma
  • Tumor marker
  • Urine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • veterinary(all)

Cite this

Detection of Canine Transitional Cell Carcinoma Using a Bladder Tumor Antigen Urine Dipstick Test. / Borjesson, Dori L; Christopher, Mary M; Ling, Gerald V.

In: Veterinary Clinical Pathology, Vol. 28, No. 1, 1999, p. 33-38.

Research output: Contribution to journalArticle

@article{0e76c8f459344c56b51202a6663077aa,
title = "Detection of Canine Transitional Cell Carcinoma Using a Bladder Tumor Antigen Urine Dipstick Test",
abstract = "Canine transitional cell carcinoma (TCC) carries a poor prognosis in part due to late disease detection. The measurement of specific tumor markers shed in the urine may aid in sensitive, early disease detection and therefore improved prognosis. A 1-year prospective clinical trial was designed to assess the efficacy, sensitivity and specificity of the first generation Bard BTA test to diagnose TCC in dogs. This test is a qualitative, rapid, latex agglutination, dipstick test run on voided urine, which measures a glycoprotein antigen complex associated with bladder cancer in human patients. Sixty-five dogs were entered in the study: 20 TCC confirmed patients, 19 healthy controls and 26 urologic controls with a variety of conditions including urinary tract infection, crystalluria and proteinuria. Overall test sensitivity was 90{\%} and specificity was 78{\%}. False positive test results were noted in the presence of significant glucosuria (4+), proteinuria (4+), and pyuria or hematuria (> 30-40 WBC or RBC per hpf). Urine parameters that had no effect on efficacy included collection method (cystocentesis or free catch), pH, specific gravity, crystalluria, bilirubinuria, bacteriuria and casts. These data indicated that the Bard BTA test was sensitive for the detection of the bladder tumor-associated antigen complex in canine TCC. As evaluated, this test may serve as a useful adjunct to diagnosis, especially when cytology or biopsy is questionable or impractical. Furthermore, because of the high sensitivity of the test, it may be a practical screening test to rule out TCC in geriatric patients or patients with clinical signs related to the lower urinary tract, particularly before pyuria and hematuria develop which may interfere with test results.",
keywords = "Dipstick, Dog, Transitional cell carcinoma, Tumor marker, Urine",
author = "Borjesson, {Dori L} and Christopher, {Mary M} and Ling, {Gerald V.}",
year = "1999",
language = "English (US)",
volume = "28",
pages = "33--38",
journal = "Veterinary Clinical Pathology",
issn = "0275-6382",
publisher = "American Society for Veterinary Clinical Pathology",
number = "1",

}

TY - JOUR

T1 - Detection of Canine Transitional Cell Carcinoma Using a Bladder Tumor Antigen Urine Dipstick Test

AU - Borjesson, Dori L

AU - Christopher, Mary M

AU - Ling, Gerald V.

PY - 1999

Y1 - 1999

N2 - Canine transitional cell carcinoma (TCC) carries a poor prognosis in part due to late disease detection. The measurement of specific tumor markers shed in the urine may aid in sensitive, early disease detection and therefore improved prognosis. A 1-year prospective clinical trial was designed to assess the efficacy, sensitivity and specificity of the first generation Bard BTA test to diagnose TCC in dogs. This test is a qualitative, rapid, latex agglutination, dipstick test run on voided urine, which measures a glycoprotein antigen complex associated with bladder cancer in human patients. Sixty-five dogs were entered in the study: 20 TCC confirmed patients, 19 healthy controls and 26 urologic controls with a variety of conditions including urinary tract infection, crystalluria and proteinuria. Overall test sensitivity was 90% and specificity was 78%. False positive test results were noted in the presence of significant glucosuria (4+), proteinuria (4+), and pyuria or hematuria (> 30-40 WBC or RBC per hpf). Urine parameters that had no effect on efficacy included collection method (cystocentesis or free catch), pH, specific gravity, crystalluria, bilirubinuria, bacteriuria and casts. These data indicated that the Bard BTA test was sensitive for the detection of the bladder tumor-associated antigen complex in canine TCC. As evaluated, this test may serve as a useful adjunct to diagnosis, especially when cytology or biopsy is questionable or impractical. Furthermore, because of the high sensitivity of the test, it may be a practical screening test to rule out TCC in geriatric patients or patients with clinical signs related to the lower urinary tract, particularly before pyuria and hematuria develop which may interfere with test results.

AB - Canine transitional cell carcinoma (TCC) carries a poor prognosis in part due to late disease detection. The measurement of specific tumor markers shed in the urine may aid in sensitive, early disease detection and therefore improved prognosis. A 1-year prospective clinical trial was designed to assess the efficacy, sensitivity and specificity of the first generation Bard BTA test to diagnose TCC in dogs. This test is a qualitative, rapid, latex agglutination, dipstick test run on voided urine, which measures a glycoprotein antigen complex associated with bladder cancer in human patients. Sixty-five dogs were entered in the study: 20 TCC confirmed patients, 19 healthy controls and 26 urologic controls with a variety of conditions including urinary tract infection, crystalluria and proteinuria. Overall test sensitivity was 90% and specificity was 78%. False positive test results were noted in the presence of significant glucosuria (4+), proteinuria (4+), and pyuria or hematuria (> 30-40 WBC or RBC per hpf). Urine parameters that had no effect on efficacy included collection method (cystocentesis or free catch), pH, specific gravity, crystalluria, bilirubinuria, bacteriuria and casts. These data indicated that the Bard BTA test was sensitive for the detection of the bladder tumor-associated antigen complex in canine TCC. As evaluated, this test may serve as a useful adjunct to diagnosis, especially when cytology or biopsy is questionable or impractical. Furthermore, because of the high sensitivity of the test, it may be a practical screening test to rule out TCC in geriatric patients or patients with clinical signs related to the lower urinary tract, particularly before pyuria and hematuria develop which may interfere with test results.

KW - Dipstick

KW - Dog

KW - Transitional cell carcinoma

KW - Tumor marker

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=0033464174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033464174&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033464174

VL - 28

SP - 33

EP - 38

JO - Veterinary Clinical Pathology

JF - Veterinary Clinical Pathology

SN - 0275-6382

IS - 1

ER -